Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

23andMe

- PMLiVE

Regeneron’s Lynozyfic granted FDA accelerated approval to treat multiple myeloma

More than 36,000 new cases of the blood cancer are expected to be diagnosed in the US this year

- PMLiVE

Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn

The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study

- PMLiVE

Regeneron to acquire human genetics company 23andMe for $256m

The agreement comes two months after 23andMe filed for bankruptcy protection

- PMLiVE

Regeneron receives positive CHMP opinion for linvoseltamab in multiple myeloma

More than 35,000 new cases of the blood cancer are diagnosed every year in Europe

- PMLiVE

Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer

Approximately 1.8 million cases of cutaneous squamous cell carcinoma are diagnosed in the US every year

- PMLiVE

Regeneron’s odronextamab recommended by CHMP to treat certain lymphomas

Follicular lymphoma and diffuse large B-cell lymphoma are collectively responsible for an estimated 283,000 global cases every year

- PMLiVE

Regeneron and Mammoth announce gene editing partnership worth $370m per target

The companies will aim to develop CRISPR-based therapies for multiple tissues and cell types

- PMLiVE

Regeneron’s Praluent receives FDA approval for paediatric patients with genetic high cholesterol

Patients aged eight year or older with heterozygous familial hypercholesterolaemia will be eligible to receive the treatment

- PMLiVE

Regeneron to acquire 2seventy’s investigational cell therapy pipeline

An estimated 150 2seventy employees will join Regeneron’s new research and development unit

- PMLiVE

Survey of US oncologists highlights advanced lung cancer research gaps  

Non-small cell lung cancer is responsible for approximately 85% of all lung cancers

- PMLiVE

Regeneron and Intellia to develop additional gene editing therapies under expanded collaboration

The companies will develop CRISPR-based therapies for neurological and muscular diseases

- PMLiVE

Regeneron’s Veopoz granted FDA approval for ultra-rare immune disease

Fewer than ten patients in the US have been diagnosed with CHAPLE disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links